Cancers

Cancers we cover

Every cancer type has its own landing page with active clinical trials, FDA-approved drugs, second-opinion steps, and oncologist directories. 22 cancers currently indexed.

Also useful: 5-year survival rates compared · trial finder across all cancers · glossary of cancer terms

Cancer types

5,396

Active trials

502

FDA-approved drugs

Bladder Cancer

199 trials 14 FDA drugs 79% 5-yr survival

Urothelial carcinoma of the bladder. Non-muscle-invasive and muscle-invasive disease both have active trial programs.

Brain Cancer

300 trials 13 FDA drugs 33% 5-yr survival

Primary brain tumors including glioblastoma multiforme (GBM), lower-grade gliomas, and other CNS malignancies.

Breast Cancer

300 trials 41 FDA drugs 91.7% 5-yr survival

The most common cancer in women in the U.S. Clinical trials test new therapies for early-stage, locally advanced, and metastatic breast cancer.

Cervical Cancer

300 trials 10 FDA drugs 68% 5-yr survival

Largely HPV-driven. Trials span prevention, early-stage (often curable with surgery + radiation), and advanced/metastatic disease.

Colorectal Cancer

300 trials 30 FDA drugs 65.4% 5-yr survival

Cancer of the colon or rectum. Trials span screening, adjuvant therapy, and metastatic disease.

Endometrial Cancer

188 trials 2 FDA drugs 81.1% 5-yr survival

The most common gynecologic cancer in the U.S. Trials focus on hormonally driven subtypes, MSI-H/dMMR immunotherapy, and advanced disease.

Esophageal Cancer

182 trials 18 FDA drugs 21.9% 5-yr survival

Squamous cell carcinoma and adenocarcinoma of the esophagus. Trials explore combination chemoradiation, immunotherapy, and perioperative regimens.

Head and Neck Cancer

300 trials 10 FDA drugs 69.5% 5-yr survival

Cancers of the oral cavity, pharynx, larynx, and salivary glands. HPV-driven and smoking-driven subtypes behave differently; trials often stratify on HPV status.

Kidney Cancer

205 trials 25 FDA drugs 78.6% 5-yr survival

Renal cell carcinoma (RCC) and related kidney malignancies.

Leukemia

300 trials 66 FDA drugs 67.8% 5-yr survival

Cancers of the blood and bone marrow. Clinical trial participation is historically higher for leukemia than most solid tumors.

Liver Cancer

196 trials 16 FDA drugs 22% 5-yr survival

Hepatocellular carcinoma (HCC) and related primary liver malignancies.

Lung Cancer

300 trials 73 FDA drugs 28.1% 5-yr survival

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Trials focus on targeted therapies, immunotherapy, and combination regimens.

Lymphoma

300 trials 27 FDA drugs 74.2% 5-yr survival

Hodgkin and non-Hodgkin lymphoma subtypes. Trials explore CAR-T therapy, bispecific antibodies, and relapsed/refractory regimens.

Melanoma

251 trials 24 FDA drugs 94.7% 5-yr survival

The most serious form of skin cancer. Trials span adjuvant, neoadjuvant, and metastatic disease — with major advances in immunotherapy.

Multiple Myeloma

265 trials 36 FDA drugs 62.4% 5-yr survival

Plasma cell malignancy. Trials test CAR-T, bispecific antibodies, and combination regimens in newly diagnosed and relapsed/refractory settings.

Ovarian Cancer

300 trials 14 FDA drugs 51.6% 5-yr survival

Epithelial ovarian cancer and related gynecologic malignancies. Trials focus on PARP inhibitors, immunotherapy, and maintenance strategies.

Pancreatic Cancer

300 trials 9 FDA drugs 13.3% 5-yr survival

One of the most aggressive cancers. Clinical trials are often the most direct path to access promising new therapies.

Prostate Cancer

300 trials 35 FDA drugs 97.9% 5-yr survival

The most common cancer in men in the U.S. Trials test hormonal, radiation, surgical, and novel therapies across risk groups.

Sarcoma

289 trials 14 FDA drugs 66% 5-yr survival

Rare cancers of bone and soft tissue. Many subtypes with distinct biology. Specialized sarcoma centers often run trials unavailable elsewhere.

Stomach Cancer

211 trials 12 FDA drugs 37.9% 5-yr survival

Gastric adenocarcinoma. Trials test perioperative chemo-immunotherapy, HER2-targeted agents, and novel therapies for advanced disease.

Testicular Cancer

29 trials 4 FDA drugs 94.9% 5-yr survival

Highly curable germ cell tumors. Trials focus on reducing toxicity of curative therapy and treating relapsed/refractory disease.

Thyroid Cancer

81 trials 9 FDA drugs 98.4% 5-yr survival

Papillary, follicular, medullary, and anaplastic thyroid carcinomas. Most are highly curable; trials focus on advanced and recurrent disease.

How we pick which cancers to cover: We prioritized the cancer types with the most search volume, highest clinical trial activity, and patient-reported information need. We add more as we expand. If a cancer you care about isn't here yet, tell us.